Taspoglutide是什么
WebTaspoglutide is a long-acting glucagon-like peptide 1 ( GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC50 value of 0.06 nM. Taspoglutide (R1583/BIM51077) is a long acting 10% formulation of (Aib8-35) human GLP-1 (7-36 amides) with 93% homology with the native polypeptide. It activates the GLP-1 receptor. WebSep 1, 2008 · This 3 arm study will assess the efficacy of taspoglutide on glycemic control (as assessed by HbA1c) in patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone, compared to placebo after 24 weeks of treatment. Patients will be randomized to one of 3 treatment arms: taspoglutide 10mg once weekly ...
Taspoglutide是什么
Did you know?
WebTaspoglutide是为治疗2型糖尿病而开发的长效GLP-1受体激动剂,EC50值为0.06nM。 … WebDec 8, 2010 · Aim: Glucagon-like peptide-1 (GLP-1) has protective effects on pancreatic β-cells.We evaluated the effects of a novel, long-acting human GLP-1 analogue, taspoglutide, on β-cells in vitro and in vivo.. Methods: Proliferation of murine pancreatic β (MIN6B1) cells and rat islets in culture was assessed by imaging of 5-ethynyl-2′-deoxyuridine-positive …
WebFeb 10, 2012 · Taspoglutide is a human glucagon-like peptide 1 analog with a pharmacokinetic profile suitable for once-weekly subcutaneous administration ().In a phase 2 clinical trial, once-weekly taspoglutide added to metformin lowered HbA 1c by up to 1%, reduced body weight, and was generally well tolerated ().The efficacy and safety of … WebSep 1, 2008 · This 3 arm study will assess the efficacy of taspoglutide on glycemic …
WebDec 9, 2014 · Key points. Taspoglutide was being developed as a once-weekly GLP-1 receptor agonist. In a head-to-head study with exenatide twice-daily, taspoglutide was more effective in reducing HbA 1c, with similar effects on weight. An unexpectedly high number of adverse events in Phase 3 trials, including gastrointestinal symptoms and … WebTaspoglutide C152H232N40O45 CID 56842233 - structure, chemical names, …
WebAim: Glucagon-like peptide-1 (GLP-1) has protective effects on pancreatic β-cells. We evaluated the effects of a novel, long-acting human GLP-1 analogue, taspoglutide, on β-cells in vitro and in vivo. Methods: Proliferation of murine pancreatic β (MIN6B1) cells and rat islets in culture was assessed by imaging of 5-ethynyl-2'-deoxyuridine-positive cells after …
WebFeb 24, 2024 · Conclusions. This head-to-head study demonstrated that both once-weekly taspoglutide and the twice-daily exenatide significantly reduced HbA 1c, fasting plasma glucose, and body weight from ... postkantoor huissenWebDec 28, 2024 · The linkers allowed tuning the taspoglutide release over more than one order of magnitude providing stable serum levels from ~0.08 to 3 μmol/L for ~20 h. Amylin and pramlintide levels were ~20 nmol/L and stable for at least 24 h. Importantly, all peptide therapeutics were protected against proteolytic degradation within the prodrug, especially ... postkantoor hoboken kioskplaatsWebBackground: Taspoglutide (R1583/BIM51077) is a new anti diabetic drug from Hoffmann-La Roche. The compound is to be administered as a subcutaneous injection once weekly and is also effective given bi-weekly. It is a long acting 10% formulation of (Aib 8-35) human glucagon-like polypeptide-1 (7 - 36 amides) with 93% homology with the native … postkantoor etten-leur